Mexican teen battles metastatic cancer with his family by his side
His symptoms started two years ago while on a family vacation. Thirteen-year-old Manuel Sanchez Paniagua was increasingly tired, and his stomach hurt. His parents thought he must have caught a stomach bug on the trip, so when they got back to their home in Mexico City, they brought Manuel to the doctor. Unfortunately, it wasn’t just a stomach bug. Physicians told the family that Manuel had a rare cancerous tumor in his liver called hepatoblastoma. When they went in to biopsy the tumor to confirm the diagnosis, they accidentally caused severe internal bleeding, and Manuel ended up in the ICU for a week. A second opinion Once he recovered from the biopsy, Manuel began chemotherapy for the tumor. A month later when the tumor had not shrunk as expected, Manuel’s parents decided it was time to get a second opinion, but from where? “In Mexico, you ask around for the best hospital in the world, and the aunt of the friend of the cousin of the brother knows,” laughs Manuel’s father, Hector Sanchez Castillo. On the advice of the “aunt of the friend of the cousin of his brother,” Hector called Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and spoke to Dr. Carlos Rodriguez-Galindo. “He told us that the tumor was not the one that we thought it was—it was worse. There are bad tumors, and there are really bad tumors. This was one of the really bad ones.” Dr. Rodriguez-Galindo explained to Hector and his wife...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
CONCLUSIONS: Immunohistochemistry seems to be a promising option not only in clinical recognition, but also in the selection and monitoring of treatment effects. However, these methods have not yet recommended for routine clinical use. PMID: 33032462 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Publication date: Available online 10 October 2020Source: Respiratory Medicine Case ReportsAuthor(s): Vipul Patel, Tilottama Majumdar, Isha Samreen, Harpreet Grewal, Thomas Kaleekal
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Authors: Zarrabi A, Mark S PMID: 33032299 [PubMed - in process]
More News: Bleeding | Blogging | Brain | Brain Cancers | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Children | Gastric (Stomach) Cancer | Heart | Hepatoblastoma | Hepatocellular Carcinoma | Hospitals | Liver | Liver Cancer | Mexico Health | Neurology | Pediatrics | PET Scan | Urology & Nephrology